According to the American Health announcement, the company's board of directors reviewed and passed the bill and plans to sign a “Framework Cooperation Agreement” with Mega Genomics Limited. The company and its subsidiaries will carry out business cooperation on testing services, testing and related supporting products required for testing services during the validity period of the agreement, and the two parties can negotiate and adjust specific cooperation projects. This transaction involves a related transaction. The relevant directors have avoided voting. The bill still needs to be submitted to the company's shareholders' meeting for consideration, and related shareholders need to avoid voting. Furthermore, the board of directors reviewed and passed the proposal to hold the fourth extraordinary shareholders' meeting in 2026.

According to the American Health announcement, the company's board of directors reviewed and passed the bill and plans to sign a “Framework Cooperation Agreement” with Mega Genomics Limited. The company and its subsidiaries will carry out business cooperation on testing services, testing and related supporting products required for testing services during the validity period of the agreement, and the two parties can negotiate and adjust specific cooperation projects. This transaction involves a related transaction. The relevant directors have avoided voting. The bill still needs to be submitted to the company's shareholders' meeting for consideration, and related shareholders need to avoid voting. Furthermore, the board of directors reviewed and passed the proposal to hold the fourth extraordinary shareholders' meeting in 2026.